Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study

Hsu, Fred; Nichol, Alan; Toriumi, Ted; Caluwé, Alex De

doi:10.1080/0284186x.2017.1328128

Cited by 33 publications

(29 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 With the advent of TKI, Kim et al and Okuma et al proposed that the prognosis of miliary intrapulmonary metastases of EGFR mutant was worse than that of non-miliary metastases. 7,8 But this point was not supported by Hsu et al 11 The small sample size of miliary intrapulmonary metastases enrolled in these studies might contribute to the seemly paradoxical conclusions. 7,8,11 This current study revealed shorter PFS, OS, and numerically lower ORR, in this group of patients.…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

<p>Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors</p>

Tang

Zheng

et al. 2020

CMAR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 83%

“…EGFR mutations are more frequently seen in miliary intrapulmonary metastases than EGFR wild-type NSCLC. [9][10][11] Also, small-scale retrospective studies showed that patients harboring EGFR mutation with miliary pulmonary metastases had a worse prognosis. However, no underlying mechanisms were provided.…”

Section: Introductionmentioning

confidence: 99%

<p>Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors</p>

Tang

Zheng

et al. 2020

CMAR

View full text Add to dashboard Cite

“…Overexpression of EGFR and/or its ligands is frequently observed in human cancer. In addition, it has been demonstrated that activating mutations of EGFR are direct determinants of oncogenic transformation in breast, ovarian and non-small cell lung cancer (4–6). It has been demonstrated that expression of EGFR is an independent prognostic factor in thyroid cancer (7).…”

Section: Introductionmentioning

confidence: 99%

Eps15 homology domain 1 promotes the evolution of papillary thyroid cancer by regulating endocytotic recycling of epidermal growth factor receptor

Liu

Liang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Papillary thyroid cancer (PTC) is the most common type of thyroid malignancy, and it is often observed to overexpress epidermal growth factor receptor (EGFR). Previous research has indicated that EH domain-containing 1 (EHD1) is associated with EGFR-mediated endocytotic recycling in multiple tumor types. The objective of the present study was to determine the protein expression levels and clinical significance of EHD1, EGFR, caveolin-1 (CAV-1) and RAB11 family interacting protein 3 (RAB11FIP3) in PTC. PTC specimens were analyzed for EHD1, EGFR, CAV-1 and RAB11FIP3 expression via immunohistochemistry and western blotting. The associations between protein expression and clinicopathological features were assessed. EHD1, EGFR, CAV-1 and RAB11FIP3 expression levels were increased in human PTC. Additionally, the expression level of EHD1 protein was significantly associated with tumor size, lymph node metastasis and EGFR expression (P<0.05). CAV-1 was associated with tumor size and EGFR expression (P<0.05). EGFR was only associated with lymph node metastasis (P=0.027) and RAB11FIP3 was not associated with any clinicopathological characteristics. The correlations between EHD1 and EGFR (r=0.564, P<0.05), CAV-1 (r=0.865, P<0.01) and RAB11FIP3 (r=0.504, P<0.05) were statistically significant. Overall, EHD1, CAV-1 and RAB11FIP3, which are key proteins in endocytotic recycling, promote PTC tumorigenesis through the regulation of the transport of EGFR.

show abstract

“…Since almost all patients had extracranial metastases, long-term survival is not purely a function of optimal local control in the brain. None of our patients had miliary brain metastases from EGFR mutated NSCLC, a special entity that may respond to targeted systemic therapy (18). Chang et al evaluated 323 patients who underwent SRS for metastatic brain lesions (19).…”

Section: Discussionmentioning

confidence: 97%

Patterns of Treatment and Outcome in Patients With 20 or More Brain Metastases

Nieder

Yobuta

Mannsåker

2018

In Vivo

View full text Add to dashboard Cite

Background/Aim: The aim of this study was to analyze the patterns of treatment and outcomes in patients with a large number of brain metastases, arbitrarily defined as 20 or more lesions. These patients are typically excluded from studies of focal brain treatment, e.g., surgery or radiosurgery, and might have a limited prognosis. Patients and Methods: This was a retrospective single-institution analysis. Overall, 11 patients were identified from a prospectively maintained database. Results: Ten patients had received active treatment (9 whole-brain radiotherapy, 7 systemic therapy). Median survival was 5.0 months without long-term survival beyond 13 months. Patients with better performance status had numerically longer survival, however we did not identify baseline parameters with a significant impact on survival. Conclusion: While long-term survival was not observed in this small study, most patients survived long enough to experience symptomatic improvement from whole-brain radiotherapy. Therefore, we recommend multidisciplinary assessment of the patients' prognosis and systemic treatment options, and initiation of whole-brain radiotherapy if survival is not limited to 1-2 months. Advances in diagnostic imaging have facilitated detection of small intracranial lesions (1-3) and thus resulted in decreasing numbers of patients who present with 1-3 brain metastases from solid extracranial primary tumors, e.g., lung, breast, kidney cancer or malignant melanoma (4). Many patients with 1-3 brain metastases are considered adequate candidates for surgery and/or radiosurgery (SRS) (5-8). Technically, it is also 173 This article is freely accessible online.

show abstract

Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study

Abstract: Mutations in EGFR were associated with a higher rate of miliary brain and lung metastases. The presence of miliary metastases did not predict for poor overall survival.

Cited by 33 publications

References 15 publications

<p>Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors</p>

<p>Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors</p>

Eps15 homology domain 1 promotes the evolution of papillary thyroid cancer by regulating endocytotic recycling of epidermal growth factor receptor

Patterns of Treatment and Outcome in Patients With 20 or More Brain Metastases

Contact Info

Product

Resources

About